Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Registration Number
- NCT00242294
- Lead Sponsor
- AstraZeneca
- Brief Summary
The aim of the study is to investigate the effect of roflumilast (APTA-2217) on lung function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily. The study duration consists of a baseline period (4 weeks) and a treatment period (24 weeks). The study will provide further data on safety, tolerability, and effectiveness of roflumilast.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 570
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method change in lung function parameters (post-bronchodilator).
- Secondary Outcome Measures
Name Time Method pulmonary function test, COPD symptoms, rescue medication, evaluation of QOL, COPD exacerbation, adverse events, pharmacokinetics.
Trial Locations
- Locations (1)
Nycomed Japan and Mitsubishi Tanabe Oharma Corporation
🇯🇵Osaka, Japan